Global Addison’s Disease Diagnosis and Treatment Market Forecast 2018-2023
The Addison’s disease market is expected to grow modestly across the globe during the forecast period (2018-2023). The Addison disease market is being influenced by many crucial factors such as reimbursement of the expenses incurred in the treatment by Medicare and Medicaid in the US, increasing awareness in the society and physicians, rising prevalence of disease and rising health expenditure in the major economies. The disease can affect both sexes. The number of cases of Addison’s disease has seen to be growing and more prevalent than before.
The Addison’s disease market is growing considerably. However, there are some hindering factors which may restrict the growth of the market. In early stages of the disease, adrenal inefficiency can create difficulty in diagnosis and the physicians may have to review the medical history of the person & the symptoms. Under developed health infrastructure and low level of awareness among the public in many countries also leads to negligence of the disease, which can be life threatening.
Global Addison’s disease market is geographically analysed into four regions: North America, Europe, APAC and Rest of the World. The Addison’s disease has the largest market share in the North-America and Europe due to rising awareness, high health expenditure and well-developed health infrastructure in both the regions. Favourable reimbursement policies for the treatment of Addison’s disease in US has also positively affected the market growth in North America and has also improved awareness in the North-American region. Whereas the markets of other regions are still rising, owing to globally rising patients of Addison’s disease and introduction of new products from growing research and development.
The Addison’s disease market is being contributed by various companies. The major companies in the industry includes Pfizer Incorporation, ViroPharma, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Tocris Bioscience, DuoCort Pharma AB, Shire Plc, Lupin Limited, and many more… These market players are striving to maintain their position in the market through growth strategies such as merger and acquisition, product launch and partnership and collaboration.
Research methodology
The market study of Addison’s disease is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analysing various regional players, regional tax laws and policies, consumer behaviour, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Market segmentation:
Global Addison’s disease is segmented on the basis of regional outlook and following segments:
1. Global Addison Disease Market Research and Analysis, By Diagnosis
2. Global Addison Disease Market Research and Analysis, By End User
3. Global Addison Disease Market Research and Analysis, By Treatment
4. Global Addison Disease Market Research and Analysis, By Region
THE REPORT COVERS:
The Addison’s disease market is growing considerably. However, there are some hindering factors which may restrict the growth of the market. In early stages of the disease, adrenal inefficiency can create difficulty in diagnosis and the physicians may have to review the medical history of the person & the symptoms. Under developed health infrastructure and low level of awareness among the public in many countries also leads to negligence of the disease, which can be life threatening.
Global Addison’s disease market is geographically analysed into four regions: North America, Europe, APAC and Rest of the World. The Addison’s disease has the largest market share in the North-America and Europe due to rising awareness, high health expenditure and well-developed health infrastructure in both the regions. Favourable reimbursement policies for the treatment of Addison’s disease in US has also positively affected the market growth in North America and has also improved awareness in the North-American region. Whereas the markets of other regions are still rising, owing to globally rising patients of Addison’s disease and introduction of new products from growing research and development.
The Addison’s disease market is being contributed by various companies. The major companies in the industry includes Pfizer Incorporation, ViroPharma, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Tocris Bioscience, DuoCort Pharma AB, Shire Plc, Lupin Limited, and many more… These market players are striving to maintain their position in the market through growth strategies such as merger and acquisition, product launch and partnership and collaboration.
Research methodology
The market study of Addison’s disease is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analysing various regional players, regional tax laws and policies, consumer behaviour, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
- Financial reports of companies involved in the market
- Authentic Public Databases such as National Organization for Rare Disorders, National Institute of Health, Texas Department of State Health Services and others.
- Whitepapers, research-papers, and news blogs
- Company websites and their product catalogue
- Supplier Websites such as Alibaba, amazon for pricing analysis
Market segmentation:
Global Addison’s disease is segmented on the basis of regional outlook and following segments:
1. Global Addison Disease Market Research and Analysis, By Diagnosis
2. Global Addison Disease Market Research and Analysis, By End User
3. Global Addison Disease Market Research and Analysis, By Treatment
4. Global Addison Disease Market Research and Analysis, By Region
THE REPORT COVERS:
- Comprehensive research methodology of global Addison’s disease.
- This report also includes detailed and extensive market overview with key analyst insights.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global Addison’s disease.
- Insights about market determinants which are stimulating the global Addison’s disease.
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASING RATE OF CHRONIC ADRENOCORTICAL INSUFFICIENCY
3.1.2. RISING CHRONIC INFECTIONS, CANCER AND TUBERCULOSIS-CAUSES ADDISON’S DISEASE
3.1.3. NEW PRODUCT DEVELOPMENT SUCH AS QR-CODED DEVICES
3.1.4. INCREASING HEALTHCARE AND DIAGNOSTIC SERVICES
3.2. RESTRAINT
3.2.1. POOR HEALTHCARE SERVICE ACCESS AND LOWER AWARENESS IN MANY COUNTRIES
3.3. OPPORTUNITIES
3.3.1. DEVELOPMENT OF AN ARTIFICIAL ADRENAL GLAND
4. MARKET SEGMENTATION
4.1. ADDISON’S DISEASE MARKET, BY DIAGNOSIS
4.1.1. LABORATORY TESTING
4.1.2. IMAGING
4.2. ADDISON’S DISEASE MARKET, BY TREATMENT
4.2.1. ORAL CORTICOSTEROIDS
4.2.2. CORTICOSTEROIDS INJECTIONS
4.3. ADDISON’S DISEASE MARKET, BY END USER
4.3.1. HOSPITALS AND CLINICS
4.3.2. DIAGNOSTIC LABORATORIES
5. COMPETITIVE LANDSCAPE
5.1. KEY MARKET STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. OTHERS
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. OTHERS
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. OTHERS
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES INC
7.2. AMGEN PLC
7.3. BAYER AG
7.4. BIOGEN INC.
7.5. BOEHRINGER INGELHEIM GMBH
7.6. DIURNAL GROUP
7.7. DUOCORT PHARMA AB
7.8. ELI LILLY AND COMPANY
7.9. GLAXOSMITHKLINE PLC
7.10. LABORATORY CORPORATION OF AMERICA
7.11. LUPIN LIMITED
7.12. MERCK KGAA
7.13. NOVARTIS INTERNATIONAL AG
7.14. PFIZER INC
7.15. REXALL DRUGSTORE
7.16. SHIRE PLC
7.17. SWITZER LIFESCIENCE PVT. LTD.
7.18. TOCRIS BIOSCIENCE
7.19. TRINITY BIOTECH PLC
7.20. VIROPHARMA INCORPORATED
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASING RATE OF CHRONIC ADRENOCORTICAL INSUFFICIENCY
3.1.2. RISING CHRONIC INFECTIONS, CANCER AND TUBERCULOSIS-CAUSES ADDISON’S DISEASE
3.1.3. NEW PRODUCT DEVELOPMENT SUCH AS QR-CODED DEVICES
3.1.4. INCREASING HEALTHCARE AND DIAGNOSTIC SERVICES
3.2. RESTRAINT
3.2.1. POOR HEALTHCARE SERVICE ACCESS AND LOWER AWARENESS IN MANY COUNTRIES
3.3. OPPORTUNITIES
3.3.1. DEVELOPMENT OF AN ARTIFICIAL ADRENAL GLAND
4. MARKET SEGMENTATION
4.1. ADDISON’S DISEASE MARKET, BY DIAGNOSIS
4.1.1. LABORATORY TESTING
4.1.2. IMAGING
4.2. ADDISON’S DISEASE MARKET, BY TREATMENT
4.2.1. ORAL CORTICOSTEROIDS
4.2.2. CORTICOSTEROIDS INJECTIONS
4.3. ADDISON’S DISEASE MARKET, BY END USER
4.3.1. HOSPITALS AND CLINICS
4.3.2. DIAGNOSTIC LABORATORIES
5. COMPETITIVE LANDSCAPE
5.1. KEY MARKET STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. OTHERS
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. OTHERS
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. OTHERS
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES INC
7.2. AMGEN PLC
7.3. BAYER AG
7.4. BIOGEN INC.
7.5. BOEHRINGER INGELHEIM GMBH
7.6. DIURNAL GROUP
7.7. DUOCORT PHARMA AB
7.8. ELI LILLY AND COMPANY
7.9. GLAXOSMITHKLINE PLC
7.10. LABORATORY CORPORATION OF AMERICA
7.11. LUPIN LIMITED
7.12. MERCK KGAA
7.13. NOVARTIS INTERNATIONAL AG
7.14. PFIZER INC
7.15. REXALL DRUGSTORE
7.16. SHIRE PLC
7.17. SWITZER LIFESCIENCE PVT. LTD.
7.18. TOCRIS BIOSCIENCE
7.19. TRINITY BIOTECH PLC
7.20. VIROPHARMA INCORPORATED
LIST OF TABLES
Table 1 GLOBAL ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS 2017-2023 ($MILLION)
Table 2 GLOBAL LABORATORY TESTING MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
Table 3 GLOBAL IMAGING MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
Table 4 GLOBAL ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY END USER2017-2023 ($MILLION)
Table 5 GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
Table 6 GLOBAL DIAGNOSTIC LABORATORIES MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
Table 7 GLOBAL ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT 2017-2023 ($MILLION)
Table 8 GLOBAL CORTICOSTEROIDS MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
Table 9 GLOBAL CORTICOSTEROIDS INJECTIONS MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
Table 10 NORTH AMERICAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 11 NORTH AMERICAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
Table 12 NORTH AMERICAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 13 NORTH AMERICAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
Table 14 EUROPEAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 15 EUROPEAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
Table 16 EUROPEAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 17 EUROPEAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
Table 18 ASIA PACIFIC ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 19 ASIA PACIFIC ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
Table 20 ASIA PACIFIC ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 21 ASIA PACIFIC ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
Table 22 REST OF THE WORLD ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
Table 23 REST OF THE WORLD ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 24 REST OF THE WORLD ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
Table 1 GLOBAL ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS 2017-2023 ($MILLION)
Table 2 GLOBAL LABORATORY TESTING MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
Table 3 GLOBAL IMAGING MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
Table 4 GLOBAL ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY END USER2017-2023 ($MILLION)
Table 5 GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
Table 6 GLOBAL DIAGNOSTIC LABORATORIES MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
Table 7 GLOBAL ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT 2017-2023 ($MILLION)
Table 8 GLOBAL CORTICOSTEROIDS MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
Table 9 GLOBAL CORTICOSTEROIDS INJECTIONS MARKET RESEARCH AND ANALYSIS 2017-2023 ($MILLION)
Table 10 NORTH AMERICAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 11 NORTH AMERICAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
Table 12 NORTH AMERICAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 13 NORTH AMERICAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
Table 14 EUROPEAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 15 EUROPEAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
Table 16 EUROPEAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 17 EUROPEAN ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
Table 18 ASIA PACIFIC ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 19 ASIA PACIFIC ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
Table 20 ASIA PACIFIC ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 21 ASIA PACIFIC ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
Table 22 REST OF THE WORLD ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2017-2023 ($ MILLION)
Table 23 REST OF THE WORLD ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 24 REST OF THE WORLD ADDISON’S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2017-2023 ($ MILLION)
LIST OF FIGURES
Figure 1 GLOBAL ADDISON’S DISEASE MARKET SHARE BY DIAGNOSIS 2017 VS 2023 (IN %)
Figure 2 GLOBAL ADDISON’S DISEASE MARKET SHARE BY END USER 2017 VS 2023 (IN %)
Figure 3 GLOBAL ADDISON’S DISEASE MARKET SHARE BY TREATMENT 2017 VS 2023 (IN %)
Figure 4 US ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 5 CANADA ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 6 REST OF NORTH AMERICA ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 7 UK ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 8 FRANCE ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 9 GERMANY ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 10 ITALY ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 11 SPAIN ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 12 ROE ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 13 CHINA ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 14 INDIA ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 15 JAPAN ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 16 ROAPAC ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 17 REST OF THE WORLD ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 1 GLOBAL ADDISON’S DISEASE MARKET SHARE BY DIAGNOSIS 2017 VS 2023 (IN %)
Figure 2 GLOBAL ADDISON’S DISEASE MARKET SHARE BY END USER 2017 VS 2023 (IN %)
Figure 3 GLOBAL ADDISON’S DISEASE MARKET SHARE BY TREATMENT 2017 VS 2023 (IN %)
Figure 4 US ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 5 CANADA ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 6 REST OF NORTH AMERICA ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 7 UK ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 8 FRANCE ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 9 GERMANY ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 10 ITALY ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 11 SPAIN ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 12 ROE ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 13 CHINA ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 14 INDIA ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 15 JAPAN ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 16 ROAPAC ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
Figure 17 REST OF THE WORLD ADDISON’S DISEASE MARKET SIZE 2017-2023 ($MILLION)
